Latest news
Opus Genetics, Inc. 2Q 2026: Revenue $0.8M, EPS $(0.14) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 20:35:07 GMTBioAge Labs reports Q2 2026 net loss $26.1M, cash and securities $381.3M; BGE-102 Phase 2 dosing underway - TradingViewTradingView · Wed, 05 Aug 2026 21:03:15 GMTWeekly Recap: IND filing for blarcamesine and Q2 loss, cash runway - TradingViewTradingView · Mon, 03 Aug 2026 11:33:16 GMTCybin publishes corporate presentation on development of serotonergic agonists for depression, anxiety - BitgetBitget · Mon, 03 Aug 2026 07:00:00 GMTWave Life Sciences Reports Q2 2026 Results, Dosing Underway in Phase 2a INLIGHT Trial of WVE-007 and Advances RNA Editing Pipeline - Quiver QuantitativeQuiver Quantitative · Thu, 30 Jul 2026 11:44:00 GMT